Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 3/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
| ▸ | FURIN | P09958 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
| ▸ | NPY4R | P50391 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26254328 | 0.95 | MAP1LC3B (0.37) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL25826704 | 0.91 | SIRT2 (0.37) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL26254329 | 0.89 | SIRT2 (0.36) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL25826705 | 0.88 | FURIN (0.37) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL20616683 | 0.88 | SIRT5 (0.38) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL20616684 | 0.88 | SIRT5 (0.38) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL19387330 | 0.88 | SIRT5 (0.38) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL18909058 | 0.87 | FAP (0.41) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL19708234 | 0.87 | FAP (0.41) | SIRT2SIRT1MAP1LC3BFAPSIRT3 | |
| SCHEMBL20467807 | 0.87 | FAP (0.41) | SIRT2SIRT1MAP1LC3BFAPSIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGNERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287138-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | SIRT2 3713/4885SIRT1 2952/4885MAP1LC3B 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.